The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Areas of unmet need for small bowel adenocarcinoma
Karan Pandya, MD, Rutgers University, New Brunswick, NJ, highlights areas of unmet for patients with small bowel adenocarcinoma, including lack of understanding which reflects low incidence. Small bowel adenocarcinoma is often treated similarly to colorectal cancer (CRC), however, outcomes of traditional chemotherapy in small bowel adenocarcinoma is not as favourable as those seen in CRC. Additional, Dr Pandya discusses the potential of circulating tumor DNA (ctDNA) to increase understanding of small bowel adenocarcinoma disease biology. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
